Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia

Drugs

Volumn 61, Issue 12, 2001, Pages 1835-1881

  Malhotra, H S ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMINOTRANSFERASE; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; COLESTIPOL; CREATINE KINASE; CYCLOSPORIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FENOFIBRATE; FLUINDOSTATIN; FUSIDIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIUM; ERYTHROCYTE DEFORMABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID METABOLISM; MYALGIA; NONHUMAN; RHABDOMYOLYSIS; RISK FACTOR; THROMBOCYTE;

EID: 0034770421     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161120-00012     Document Type: Article

References (242)

1. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
2. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
3. Management of hypercholesterolemia
4. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
5. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease
6. Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors
7. Are all HMG-CoA reductase inhibitors (vastatins) alike?
8. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase
9. Mechanism of cholesterol lowering in casein-fed rabbits treated with atorvastatin
10. Tissue selectivity of HMG-CoA reductase inhibitors
11. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation
12. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triglyceride-lowering in rat correlates with efficacy in LDL animal models
13. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: Atorvastatin versus lovastatin
14. Plasma meva-Ionic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia
15. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia
16. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening
17. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin
18. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells
19. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
20. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity
21. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
22. Hypercholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig
23. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits
24. Effect of atorvastatin on postprandial lipoprotein metabolism in normolipidemic subjects
25. The HMG-CoA reductase inhibitor, atorvastatin, increases the fractional clearance rate of postprandial triglyceride rich lipoproteins
26. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia
27. Effects of atorvastatin in patients with homozygous familial hypercholesterolemia
28. Effect of atorvastatin on low-density lipoprotein subfraction profile
29. Atorvastatin and LDL subclass distribution
30. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
31. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
32. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients
33. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women
34. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
35. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance
36. Atorvastatin reduces NF-kappa B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells
37. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
38. Pleiotropic effects of statins in atherosclerosis and diabetes
39. Effect of the new HMG-CoA reductase inhibitor atorvastatin on human vascular cell growth in mono- and cocultures in comparison to lovastatin
40. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects
41. Lipid-lowering and anti-aggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia
42. Effects of atorvastatin on platelet aggregation in whole blood
43. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients
44. Effects of atorvastatin treatment on global fibrinolytic capacity, apoptosis, and leukocyte activation in patients with coronary artery disease
45. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit
46. Effect of HMG-CoA reductase inhibitors therapy on C-reactive protein levels
47. Atorvastatin decreases elevated levels of C-reactive protein in patients with cardiovascular disease and mixed dyslipidaemia: The ATOMIX Study
48. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia
49. Dose dependent effects of atorvastatin on C-reactive protein in type 2 diabetes mellitus
50. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia
51. Effect of atorvastatin on plasma fibrinogen
52. Statins and fibrinogen
53. Effects of atorvastatin on plasma homocysteine levels in subjects with familial hypercholesterolemia
54. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia
55. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
56. More on atorvastatin and fibrinogen
57. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
58. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling
59. Comparative study of HMG-CoA reductase inhibitors on fibrinogen
60. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
61. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
62. Endothelium in control
63. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
64. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
65. Atorvastatin improves endothelial function in renal transplant recipients
66. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: A double-blind study
67. Hypercholesterolemia increases endothelial superoxide anion production
68. Atorvastatin reduces the blood levels of vascular endothelial growth factor in patients with coronary artery disease
69. Reduction in LDL cholesterol improves RBC deformability in patients with primary hypercholesterolemia
70. Effects of atorvastatin on the fibrinolytic system in patients with primary hypercholesterolemia
71. Inflammation markers and coronary heart disease
72. C-reactive protein, inflammation, and coronary risk
73. Do different statins possess different antiinflammatory and antithrombogenic properties?
74. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary artery disease: Meta-analyses of prospective studies
75. Hemostatic risk factors and prevalent coronary heart disease: The FINRISK study
76. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. A pilot, randomised, double-blind, dose-titrating study
77. Statins and fibrinogen
78. New insights into the pharmacodynamic and pharmacokinetic properties of statins
79. Absolute bioavailability of atorvastatin in man
80. Pharmacokinetic studies on CI-981 (3): In vitro and in vivo plasma protein binding
81. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase
82. Atorvastatin (CI-981) clinical pharmacokinetic study (III) - Effect of food on bioavailability of atorvastatin
83. Atorvastatin (CI-981) clinical pharmacokinetic study (II) - Pharmacokinetics of single dose atorvastatin in healthy male volunteers
84. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor
85. Metabolism and excretion of atorvastatin in rats and dogs
86. Atorvastatin (CI-981) clinical pharmacokinetic study (IV) - Pharmacokinetics of multiple dose atorvastatin in healthy male volunteers
87. Atorvastatin in the treatment of severe hypercholesterolemia
88. Effect of age and gender on pharmacokinetics of atorvastatin in humans [437340]
89. Effects of hepatic and renal impairment on pharmacokinetics (PK) and pharmacodynamics (PD) of atorvastatin
90. Effects of Maalox TC on pharmacokinetics and pharmacodynamics of atorvastatin
91. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction
92. Statins do more than just lower cholesterol
93. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
94. Effect of itraconazole on the pharmacokinetics of atorvastatin
95. Erythromycin coadministration increases plasma atorvastatin concentrations
96. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
97. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
98. Concomitant administration of ABT-378/ritonavir (ABT-378r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA)
99. Efficacy and safety of atorvastatin after pediatric cardiac transplantation
100. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
101. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients
102. Role of statins in the management of dyslipidemia after cardiac transplant: Randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin
103. Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation
104. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III)
105. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
106. A multicenter, placebo-controlled, dose-ranging study of atorvastatin
107. Efficacy of atorvastatin in primary hypercholesterolemia
108. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals
109. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
110. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a double-masked study
111. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: A randomized, placebo-controlled study
112. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
113. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
114. Effect of statin therapy on HDL-C levels in patients with type IIa and type IIb hyperlipidemia
115. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia
116. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia
117. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia
118. Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia
119. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice
120. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
121. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
122. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial
123. Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin
124. Simvastatin and atorvastatin have different effects at high doses on high density lipoprotein cholesterol and apolipoprotein A-I
125. Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia
126. Comparing treatment success with statins: Results from the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS)
127. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah
128. Evidence based approach for management of mixed hyperlipidemia
129. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia
130. Comparison of atorvastatin and bezafibrate treatment in dyslipidemic patients with metabolic syndrome (MS)
131. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate
132. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia
133. Lowering effects of four different statins on serum triglyceride level
134. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks
135. Comparison of statins in hypertriglyceridemia
136. Diabetic dyslipidaemia: Current treatment recommendations
137. Triglyceride is the major atherogenic lipid in NIDDM
138. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
139. Strategies for the management of diabetic dyslipidaemia
140. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study
141. Atorvastatin is effective and safe in patients with NIDDM: A multicenter, open-label study
142. Does the presence of either concurrent hypertension or non-insulin-dependent diabetes mellitus affect the efficacy and safety of atorvastatin in patients with hyperlipidaemia?
143. The Can-ADA Study: Do lipid parameters respond differently to atorvastatin therapy in ischemic heart disease subjects with and without type 2 diabetes?
144. Effectiveness of statin treatment in reducing vascular risk in type 2 diabetes: Comparison between fluvastatin, simvastatin and atorvastatin
145. Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia
146. The ASSET Investigators. The efficacy and safety of atorvastatin versus simvastatin in mixed dyslipidemic patients with type 2 diabetes mellitus during 54 weeks
147. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI Study: A double-blind, randomised placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
148. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience
149. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia
150. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
151. High-dose atorvastarin therapy in severe heterozygous familial hypercholesterolaemia
152. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias
153. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia
154. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
155. A multicenter, open-label, randomized study comparing the efficacy of atorvastatin versus usual care in reducing refractory hypercholesterolemia in high-risk patients to target levels
156. Comparison of atorvastatin alone versus simvastatin ± cholestyramine in the management of severe primary hypercholesterolaemia (the Six Cities Study)
157. Treating patients with documented atherosclerosis to National Cholesterol Education Program - Recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
158. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)
159. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: The Atorvastatin Matrix Study
160. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis
161. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidaemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH)
162. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease
163. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
164. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
165. Can aggressive lipid-lowering therapy provide additional clinical benefit? Subgroup analysis of the Atorvastatin VErsus Revascularization Treatments (AVERT) trial
166. Atorvastatin for refractory hypercholesterolemia in heart transplant patients
167. Safety and efficacy of atorvastatin in heart transplant recipients
168. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins
169. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment
170. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
171. Atorvastatin for protease inhibitor-related hyperlipidaemia
172. Hyperlipidemia in patients with chronic renal disease
173. Should hyperlipidaemia in dialysis patients be treated?
174. Clinical epidemiology of cardiovascular disease in chronic renal disease
175. A placebo-controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD
176. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis
177. Correction of hypercholesterolaemia in haemodialysis patients with atorvastatin
178. Safety and efficacy of atorvastatin in patients with severe renal dysfunction
179. Vitaestat 1: A prospective randomised placebo controlled trial with a-tocopherol and atorvastatin in patients in hemo- and peritoneal dialysis
180. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor
181. Toxic epidermal necrolysis from atorvastatin
182. Atorvastatin-induced severe thrombocytopenia
183. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels
184. Two year safety of atorvastatin compared to lovastatin in patients with hypercholesterolemia
185. Cholestatic liver dysfunction
186. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupuserythematosus. Grupo Lupus Virgen de las Nieves
187. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin
188. Atorvastatin-induced dermatomyositis
189. Rhabdomyolysis after taking atorvastatin with gemfibrozil
190. Acute rhabdomyolysis after atorvastatin and fusidic acid therapy
191. Cost-effectiveness of statins
192. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction
193. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia
194. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES Study
195. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin
196. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
197. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels
198. Cost of treatment of hypercholesterolaemia to NHF goals in Australia
199. The cost-effectiveness of statins: Evidence from the ACCESS trial
200. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study Group (4S)
201. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease
202. Safety of pravastatin in long-term trials conducted in the United States
203. Adverse reactions profile: 10. simvastatin and pravastatin
204. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
205. Choosing drug therapy for patients with hyperlipidemia
206. Lipid lowering in the patient at risk - The next decade of discovery
207. Is the relationship between serum cholesterol and the risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
208. Maximizing the cost-effectiveness of lipid-lowering therapy
209. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
210. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
211. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
212. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TEXCAPS
213. Pro and con: Low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
214. Risk factors for a major coronary event after myocardial infarction in the Scandianavian Simvastatin Survival Study (4S): Impact of predicted risk on the benefit of cholesterol-lowering treatment
215. Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease
216. The Anglo-Scandinavian Cardiac Outcomes Trial
217. A 4-year, placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin dependent diabetes mellitus
218. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
219. Effect of greater LDL-C reductions on prognosis - The Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial
220. Stroke prevention by aggressive reduction in cholesterol levels - The SPARCL study
221. Effect of lowering LDL-C beyond currently recommended targets - The treating to new targets study
222. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolaemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial
223. Assessing the effects of statins on atherosclerosis progression using intravascular ultrasound: Rationale and design of the REVERSAL study
224. Effects of atorvasatin on exercise time in patients with intermittent claudication (IC) due to peripheral arterial disease (PAD) [poster]
225. Effects of serivastatin and atorvastatin on dyslipidaemia of peritoneal dialysis patients
226. CAVEAT: A randomised, double-blind, parallel group evaluation of cerivastatin 0.4mg and 0.8mg compared to atorvastatin 10mg and 20mg once daily in patients with combined (type IIB) dyslipidaemia
227. Comparison of the efficacy and safety of atorvastatin versus cerivastatin in patients with hypercholesterolemia
228. Should reductase inhibitor therapy to lower cholesterol be instituted in the setting of an acute coronary event? [1]
229. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease [2]
230. Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the Atorvastatin Versus Revascularization (AVERT) Trial
231. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
232. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial
233. Lipoprotein changes and reduction in incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study
234. Treatment of diabetic dyslipidemia
235. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease
236. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?